Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review)
- Authors:
- Honglian Yu
- Qiang Bian
- Xin Wang
- Xinzhe Wang
- Luhao Lai
- Zhichun Wu
- Zhankui Zhao
- Bo Ban
-
Affiliations: Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272029, P.R. China, Collaborative Innovation Center, Jining Medical University, Jining, Shandong 272067, P.R. China, Department of Urology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272029, P.R. China, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China - Published online on: January 18, 2024 https://doi.org/10.3892/or.2024.8704
- Article Number: 45
-
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, Solomon A and Saito S: A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 84:1922–1930. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Neil SJ, Zang T and Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 451:425–430. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mahauad-Fernandez WD and Okeoma CM: The role of BST-2/Tetherin in host protection and disease manifestation. Immun Inflamm Dis. 4:4–23. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cai D, Cao J, Li Z, Zheng X, Yao Y, Li W and Yuan Z: Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 9:1022009. View Article : Google Scholar : PubMed/NCBI | |
|
Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, Bolloré K, Vendrell JP, Le Gallou S, Mourcin F, et al: Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 187:3931–3941. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D and Klein B: An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 114:5173–5181. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Erikson E, Adam T, Schmidt S, Lehmann-Koch J, Over B, Goffinet C, Harter C, Bekeredjian-Ding I, Sertel S, Lasitschka F and Keppler OT: In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci USA. 108:13688–13693. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Hirano T and Tsuchiya M: Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun. 258:583–591. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B and Yong KL: Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res. 11:3377–3384. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, et al: Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene. 26:1971–1982. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Li Y, Feng S, Guan Y and Cao Y: MicroRNA-760 inhibits cell viability and migration through down-regulating BST2 in gastric cancer. J Biochem. 168:159–170. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kong Y, Xue Z, Wang H, Cui G, Chen A, Liu J, Wang J, Li X and Huang B: Identification of BST2 contributing to the development of glioblastoma based on bioinformatics analysis. Front Genet. 13:8901742022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Nishioka Y, Ozaki S, Jalili A, Abe S, Kakiuchi S, Kishuku M, Minakuchi K, Matsumoto T and Sone S: HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother. 58:967–976. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kuang CM, Fu X, Hua YJ, Shuai WD, Ye ZH, Li Y, Peng QH, Li YZ, Chen S, Qian CN, et al: BST2 confers cisplatin resistance via NF-kappaB signaling in nasopharyngeal cancer. Cell Death Dis. 8:e28742017. View Article : Google Scholar : PubMed/NCBI | |
|
Fang KH, Kao HK, Chi LM, Liang Y, Liu SC, Hseuh C, Liao CT, Yen TC, Yu JS and Chang KP: Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer. Laryngoscope. 124:E354–E360. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jin H, Zhang L, Wang S and Qian L: BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway. Arch Med Sci. 17:1772–1782. 2019.PubMed/NCBI | |
|
Liu G, Du X, Xiao L, Zeng Q and Liu Q: Activation of FGD5-AS1 promotes progression of cervical cancer through regulating BST2 to inhibit macrophage M1 Polarization. J Immunol Res. 2021:58572142021. View Article : Google Scholar : PubMed/NCBI | |
|
Sayeed A, Luciani-Torres G, Meng Z, Bennington JL, Moore DH and Dairkee SH: Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS One. 8:e671912013. View Article : Google Scholar : PubMed/NCBI | |
|
Lei C, Hou Y and Chen J: Specificity protein 1-activated bone marrow stromal cell antigen 2 accelerates pancreatic cancer cell proliferation and migration. Exp Ther Med. 22:14592021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Wang Y, Xue F, Guan E, Tian F, Xu J and Zhang H: BST2 promotes tumor growth via multiple pathways in hepatocellular carcinoma. Cancer Invest. 38:329–337. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SC, Hong CW, Jang SG, Kim YA, Yoo BC, Shin YK, Jeong SY, Ku JL and Park JG: Establishment and characterization of paired primary and peritoneal seeding human colorectal cancer cell lines: Identification of genes that mediate metastatic potential. Transl Oncol. 11:1232–1243. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mukai S, Oue N, Oshima T, Mukai R, Tatsumoto Y, Sakamoto N, Sentani K, Tanabe K, Egi H, Hinoi T, et al: Overexpression of Transmembrane Protein BST2 is associated with poor survival of patients with esophageal, gastric, or colorectal cancer. Ann Surg Oncol. 24:594–602. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang LL, Wu L, Yu GT, Zhang WF, Liu B and Sun ZJ: CD317 signature in head and neck cancer indicates poor prognosis. J Dent Res. 97:787–794. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang LQ, Hu HY, Han Y, Tang ZY, Gao J, Zhou QY, Liu YX, Chen HS, Xu TN, Ao L, et al: CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription. Cancer Gene Ther. 29:1895–1907. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Shigematsu Y, Oue N, Nishioka Y, Sakamoto N, Sentani K, Sekino Y, Mukai S, Teishima J, Matsubara A and Yasui W: Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer. Oncol Lett. 14:999–1004. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng J, Liu Z, Deng T, Lu Z, Liu M, Lu X, Adeshakin FO, Yan D, Zhang G and Wan X: CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection. Mol Immunol. 129:94–102. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J and Tanaka Y: HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem. 284:15927–15941. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Naushad W, Mahauad-Fernandez WD and Okeoma CM: Structural determinant of BST-2-mediated regulation of breast cancer cell motility: A role for cytoplasmic tail tyrosine residues. Oncotarget. 8:110221–110233. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Andrew AJ, Miyagi E, Kao S and Strebel K: The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology. 6:802009. View Article : Google Scholar : PubMed/NCBI | |
|
Swiecki M, Scheaffer SM, Allaire M, Fremont DH, Colonna M and Brett TJ: Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem. 286:2987–2997. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC and Bieniasz PD: Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 139:499–511. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A and Banting G: BST-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 4:694–709. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Edgar JR, Manna PT, Nishimura S, Banting G and Robinson MS: Tetherin is an exosomal tether. Elife. 5:e171802016. View Article : Google Scholar : PubMed/NCBI | |
|
Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R and Guatelli J: Stimulation of NF-kappaB activity by the HIV restriction factor BST2. J Virol. 87:2046–2057. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Billcliff PG, Rollason R, Prior I, Owen DM, Gaus K and Banting G: CD317/tetherin is an organiser of membrane microdomains. J Cell Sci. 126((Pt 7)): 1553–1564. 2013.PubMed/NCBI | |
|
Billcliff PG, Gorleku OA, Chamberlain LH and Banting G: The cytosolic N-terminus of CD317/tetherin is a membrane microdomain exclusion motif. Biol Open. 2:1253–1263. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jones DR and Varela-Nieto I: The role of glycosyl-phosphatidylinositol in signal transduction. Int J Biochem Cell Biol. 30:313–326. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Muller GA and Muller TD: (Patho)physiology of glycosylphosphatidylinositol-anchored proteins I: Localization at plasma membranes and extracellular compartments. Biomolecules. 13:8552023. View Article : Google Scholar : PubMed/NCBI | |
|
Galao RP, Le Tortorec A, Pickering S, Kueck T and Neil SJ: Innate sensing of HIV-1 assembly by Tetherin induces NF-kappaB-dependent proinflammatory responses. Cell Host Microbe. 12:633–644. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Holmgren AM, Miller KD, Cavanaugh SE and Rall GF: Bst2/tetherin is induced in neurons by type I interferon and viral infection but is dispensable for protection against neurotropic viral challenge. J Virol. 89:11011–11018. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rahmani W, Chung H, Sinha S, Bui-Marinos MP, Arora R, Jaffer A, Corcoran JA, Biernaskie J and Chun J: Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids. iScience. 25:1038182022. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W, Bover L, Cho MW, Wen XX, Hanabuchi S, Bao MS, Rosen DB, Wang YH, Shaw JL, Du Q, et al: Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med. 206:1603–1614. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cao W and Bover L: Signaling and ligand interaction of ILT7: Receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev. 234:163–176. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yi E, Oh J, Kang HR, Song MJ and Park SH: BST2 inhibits infection of influenza A virus by promoting apoptosis of infected cells. Biochem Biophys Res Commun. 509:414–420. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, et al: Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 107:1570–1581. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mahauad-Fernandez WD and Okeoma CM: B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells. Sci Rep. 8:43052018. View Article : Google Scholar : PubMed/NCBI | |
|
Oue N, Sentani K, Sakamoto N, Uraoka N and Yasui W: Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int J Clin Oncol. 24:771–778. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M: Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 24 (Suppl 2):S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mahauad-Fernandez WD, Naushad W, Panzner TD, Bashir A, Lal G and Okeoma CM: BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells. Sci Rep. 8:176082018. View Article : Google Scholar : PubMed/NCBI | |
|
Woodman N, Pinder SE, Tajadura V, Le Bourhis X, Gillett C, Delannoy P, Burchell JM and Julien S: Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer. Int J Oncol. 49:265–275. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Deng H, Guan X, Gong L, Zeng J, Zhang H, Chen MY and Li G: CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer. Sci Rep. 9:1972019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu S, Liu Y, Ma H, Fang S, Wei S, Li X, Lu Z, Zheng Y, Liu T, Zhu X, et al: A novel signature integrated of immunoglobulin, glycosylation and anti-viral genes to predict prognosis for breast cancer. Front Genet. 13:8347312022. View Article : Google Scholar : PubMed/NCBI | |
|
Du Y, Yuan S, Zhuang X, Zhang Q and Qiao T: Multiomics differences in lung squamous cell carcinoma patients with high radiosensitivity index compared with those with low radiosensitivity index. Dis Markers. 2021:37666592021. View Article : Google Scholar : PubMed/NCBI | |
|
Mahauad-Fernandez WD, DeMali KA, Olivier AK and Okeoma CM: Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis. Breast Cancer Res. 16:4932014. View Article : Google Scholar : PubMed/NCBI | |
|
Mahauad-Fernandez WD, Borcherding NC, Zhang W and Okeoma CM: Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells. PLoS One. 10:e01239312015. View Article : Google Scholar : PubMed/NCBI | |
|
Yi EH, Yoo H, Noh KH, Han S, Lee H, Lee JK, Won C, Kim BH, Kim MH, Cho CH and Ye SK: BST-2 is a potential activator of invasion and migration in tamoxifen-resistant breast cancer cells. Biochem Biophys Res Commun. 435:685–690. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PH, Mahauad-Fernandez WD, Madison MN and Okeoma CM: BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. Virology. 444:124–139. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mahauad-Fernandez WD and Okeoma CM: Cysteine-linked dimerization of BST-2 confers anoikis resistance to breast cancer cells by negating proapoptotic activities to promote tumor cell survival and growth. Cell Death Dis. 8:e26872017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Castro-Gonzalez S, Chen Y and Serra-Moreno R: Effects of the SUMO Ligase BCA2 on metabolic activity, cell proliferation, cell migration, cell cycle, and the regulation of NF-kappaB and IRF1 in different breast epithelial cellular contexts. Front Cell Dev Biol. 9:7114812021. View Article : Google Scholar : PubMed/NCBI | |
|
Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD and Fichtner I: Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther. 4:151–168. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ma JH, Qin L and Li X: Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 18:332020. View Article : Google Scholar : PubMed/NCBI | |
|
Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von Kockritz-Blickwede M, Schilling B, Brandau S, Weiss S and Jablonska J: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 138:1982–1993. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pylaeva E, Lang S and Jablonska J: The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils. Front Immunol. 7:6292016. View Article : Google Scholar : PubMed/NCBI | |
|
García-Pras E, Fernández-Iglesias A, Gracia-Sancho J and Pérez-Del-Pulgar S: Cell death in hepatocellular carcinoma: Pathogenesis and therapeutic opportunities. Cancers (Basel). 14:482021. View Article : Google Scholar : PubMed/NCBI | |
|
Tayob N, Kanwal F, Alsarraj A, Hernaez R and El-Serag HB: The Performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): A phase 3 biomarker study in the United States. Clin Gastroenterol Hepatol. 21:415–423.e4. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y and Deng B: Hepatocellular carcinoma: Molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 42:629–652. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Zheng B, Zhou X, Zheng T, Wang H, Wang Y and Zhang W: Increased BST-2 expression by HBV infection promotes HBV-associated HCC tumorigenesis. J Gastrointest Oncol. 12:694–710. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang G, Li X, Chen Q, Li J, Ruan Q, Chen YH, Yang X and Wan X: CD317 Activates EGFR by regulating its association with lipid rafts. Cancer Res. 79:2220–2231. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pan XB, Han JC, Cong X and Wei L: BST2/tetherin inhibits dengue virus release from human hepatoma cells. PLoS One. 7:e510332012. View Article : Google Scholar : PubMed/NCBI | |
|
Dafa-Berger A, Kuzmina A, Fassler M, Yitzhak-Asraf H, Shemer-Avni Y and Taube R: Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology. 428:98–111. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pan XB, Qu XW, Jiang D, Zhao XL, Han JC and Wei L: BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res. 98:54–60. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mollinedo F and Gajate C: Lipid rafts as signaling hubs in cancer cell survival/death and invasion: Implications in tumor progression and therapy. Thematic Review Series: Biology of Lipid Rafts. J Lipid Res. 61:611–635. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA and Bray F: Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 159:335–349.e15. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Cao Y, Guan Y and Zheng C: BST2 promotes cell proliferation, migration and induces NF-kappaB activation in gastric cancer. Biotechnol Lett. 40:1015–1027. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM and Yasui W: Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: Expression of DSC2 in gastric cancer with intestinal phenotype. J Pathol. 221:275–284. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez A, Corchete LA, Alcazar JA, Montero JC, Rodriguez M, Chinchilla-Tabora LM, Vidal Tocino R, Moyano C, Muñoz-Bravo S, Sayagués JM and Abad M: Dysregulated expression of three genes in colorectal cancer stratifies patients into three risk groups. Cancers (Basel). 14:40762022. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang SF, Kan CY, Hsiao YC, Tang R, Hsieh LL, Chiang JM, Tsai WS, Yeh CY, Hsieh PS, Liang Y, et al: Bone marrow stromal antigen 2 is a novel plasma biomarker and prognosticator for colorectal carcinoma: A secretome-based verification study. Dis Markers. 2015:8740542015. View Article : Google Scholar : PubMed/NCBI | |
|
Shen C, Luo C, Xu Z, Liang Q, Cai Y, Peng B, Yan Y and Xia F: Molecular patterns based on immunogenomic signatures stratify the prognosis of colon cancer. Front Bioeng Biotechnol. 10:8200922022. View Article : Google Scholar : PubMed/NCBI | |
|
Chu CH, Chang SC, Wang HH, Yang SH, Lai KC and Lee TC: Prognostic values of EPDR1 hypermethylation and its inhibitory function on tumor invasion in colorectal cancer. Cancers (Basel). 10:3932018. View Article : Google Scholar : PubMed/NCBI | |
|
He X, Chen H, Zhong X, Wang Y, Hu Z, Huang H, Zhao S, Wei P, Shi D and Li D: BST2 induced macrophage M2 polarization to promote the progression of colorectal cancer. Int J Biol Sci. 19:331–345. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario Garcia-Campelo M, Lazaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, et al: Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 10:e0053202022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YC, Lin MC, Hsiao CC, Zheng YX, Chen KD, Sung MT, Chen CJ, Wang TY, Lin YY, Chang HC, et al: Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma. Oncotarget. 8:45710–45724. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Tang L, Chen Y, Zhang Y and Zhuang W: An immune panel signature predicts prognosis of lung adenocarcinoma patients and correlates with immune microenvironment. Front Cell Dev Biol. 9:7979842021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T and Sone S: Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer. 63:23–31. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wainwright DA, Balyasnikova IV, Han Y and Lesniak MS: The expression of BST2 in human and experimental mouse brain tumors. Exp Mol Pathol. 91:440–446. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, et al: Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int J Cancer. 132:472–484. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pham QT, Oue N, Yamamoto Y, Shigematsu Y, Sekino Y, Sakamoto N, Sentani K, Uraoka N, Tiwari M and Yasui W: The Expression of BTS-2 enhances cell growth and invasiveness in renal cell carcinoma. Anticancer Res. 37:2853–2860. 2017.PubMed/NCBI | |
|
Pan XQ, Huang W, Jin LW, Lin HZ and Xu XY: A novel pyroptosis-related prognostic signature for risk stratification and clinical prognosis in clear cell renal cell carcinoma. Dis Markers. 2022:80938372022. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada Y, Arai T, Sugawara S, Okato A, Kato M, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N: Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma. Cancer Sci. 109:1239–1253. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Januchowski R, Sterzynska K, Zawierucha P, Rucinski M, Swierczewska M, Partyka M, Bednarek-Rajewska K, Brązert M, Nowicki M, Zabel M and Klejewski A: Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget. 8:49944–49958. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Cai Y, Zheng L, Zhang Z, Lin X and Jiang N: LncRNA BISPR promotes the progression of thyroid papillary carcinoma by regulating miR-21-5p. Int J Immunopathol Pharmacol. 32:20587384187726522018. View Article : Google Scholar : PubMed/NCBI | |
|
Milutin Gasperov N, Farkas SA, Nilsson TK and Grce M: Epigenetic activation of immune genes in cervical cancer. Immunol Lett. 162((2 Pt B)): 256–257. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, et al: DNA methylation in glioblastoma: Impact on gene expression and clinical outcome. BMC Genomics. 11:7012010. View Article : Google Scholar : PubMed/NCBI | |
|
Kawai S, Azuma Y, Fujii E, Furugaki K, Ozaki S, Matsumoto T, Kosaka M and Yamada-Okabe H: Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 99:2461–2466. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gu G, Zhao D, Yin Z and Liu P: BST-2 binding with cellular MT1-MMP blocks cell growth and migration via decreasing MMP2 activity. J Cell Biochem. 113:1013–1021. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yoo H, Park SH, Ye SK and Kim M: IFN-γ-induced BST2 mediates monocyte adhesion to human endothelial cells. Cell Immunol. 267:23–29. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sibler E, He Y, Ducoli L, Rihs V, Sidler P, Puig-Moreno C, Frey J, Fujimoto N, Detmar M and Dieterich LC: Immunomodulatory responses of subcapsular sinus floor lymphatic endothelial cells in tumor-draining lymph nodes. Cancers (Basel). 14:36022022. View Article : Google Scholar : PubMed/NCBI | |
|
Werner TA, Forster CM, Dizdar L, Verde PE, Raba K, Schott M, Knoefel WT and Krieg A: CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma. Br J Cancer. 117:1837–1845. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bian S, Zhao Y, Li F, Lu S, He Z, Wang S, Bai X, Zhao D, Liu M and Wang J: Total ginsenosides induce autophagic cell death in cervical cancer cells accompanied by downregulation of bone marrow stromal antigen-2. Exp Ther Med. 22:6672021. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng J, Zhang G, Deng T, Liu Z, Zhang M, Zhang P, Adeshakin FO, Niu X, Yan D, Wan X and Yu G: CD317 maintains proteostasis and cell survival in response to proteasome inhibitors by targeting calnexin for RACK1-mediated autophagic degradation. Cell Death Dis. 14:3332023. View Article : Google Scholar : PubMed/NCBI | |
|
Yang LL, Mao L, Wu H, Chen L, Deng WW, Xiao Y, Li H, Zhang L and Sun ZJ: pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma. Oral Oncol. 96:131–139. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S and Pan L: Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 7:392022. View Article : Google Scholar : PubMed/NCBI | |
|
Wu RQ, Lao XM, Chen DP, Qin H, Mu M, Cao WJ, Deng J, Wan CC, Zhan WY, Wang JC, et al: Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. Immunity. 56:180–192.e11. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Rimassa L, Finn RS and Sangro B: Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 79:506–515. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Staudinger M, Glorius P, Burger R, Kellner C, Klausz K, Gunther A, Repp R, Klapper W, Gramatzki M and Peipp M: The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. Blood Cancer J. 4:e2192014. View Article : Google Scholar : PubMed/NCBI | |
|
Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, et al: Identification of a new HLA-A2-restricted T-cell, epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol. 34:486–496. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hiramatsu K, Serada S, Kobiyama K, Nakagawa S, Morimoto A, Matsuzaki S, Ueda Y, Fujimoto M, Yoshino K, Ishii KJ, et al: CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody. Cancer Sci. 106:1474–1478. 2015. View Article : Google Scholar : PubMed/NCBI |
